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ABSTRACT
Objectives: The Rh blood group system is one of the most
important and immunogenic blood group systems after
the ABO blood group system and, like other blood group
antigens, it follows ethnic and racial trends. However,
when it comes to D variants—partial D and weak D—
most of the cohorts studied in the literature have been of
European descent. This study aimed to discover the variant
D trends in Detroit, Michigan, with an emphasis on Black
communities.
Methods: From 2016 to 2018, there were 102 patients
(women of childbearing potential: < 50 years) at
Henry Ford Hospital that had serologic D discrepant
testing. These patients were sent out for molecular RHD
determination.
Results: In total, 12.7% of patients were characterized
as RhD positive and 87.3% of patients were characterized
as RhD variants (nominated as RhD negative at our
institution).
Conclusions: Our predominantly Black cohort sheds
light on the diversity of the RhD antigen. The majority
of Blacks were classified as RhD variants (RhD negative
nomination at our institution). Therefore, molecular
testing for this patient population with serologic RhD
discrepancies is paramount to properly manage their
obstetric care.

© American Society for Clinical Pathology, 2021. All rights reserved.
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Key Points
• Knowing that Detroit’s racial and ethnic composition does not fit the
European cohorts that are prevalent in the literature, we decided to
quantify the prevalence of variant RhDs in this population.
• RHD alleles vary among various racial and ethnic groups.
• Women of childbearing potential in Black communities are at an
increased risk for having serologic D antigen discrepancies that are
consistent with potential alloimmunization and HDFN.

The Rh blood group system is one of the most important blood group systems after the ABO blood group
system. Its implications are interdisciplinary and reach
from transfusion medicine all the way to fetal-maternal
medicine. As is known, Rh alloimmunization is a significant cause of morbidity during pregnancy, as it causes
hemolytic disease of the fetus and newborn (HDFN).1
Typically, individuals are either positive or negative for
the D antigen. Alloimmunization can occur when the individual is RhD negative, hence pregnant women are given
prophylaxis with Rh immune globulin (RhIG) to prevent
alloimmunization and HDFN.2 Problems arise, however,
when individuals—especially pregnant women—are classified as having a D variant.1
The D antigen class includes 3 broad categories: RhD
positive, RhD negative, and RhD variant. The RhD variant includes weak D or partial D. In standard blood
bank practice, serologic testing—via automation or tube
testing—can help detect potential RhD discrepancies in
patients. Testing using 2 different clones of monoclonal
anti-D reagent provides the ability to detect discrepancies
in RhD patient samples. Discrepancies take on the form
of an undetermined strength (usually characterized by a
question mark) in one or both of the monoclonal anti-D
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Materials and Methods
Serologic Analysis
Beginning January 2016, patient samples showing
inconclusive results with anti-D through automated
testing were subject to manual serologic investigation via tube testing. Automated analysis was conducted on an Immucor NEO. Direct hemagglutination
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microstrips were used for blood typing: strips included
a monoclonal control, anti-A, anti-B, anti-D-series 4,
anti-D-series 5, A1 cell, and B cell well. All reagents
used were from Immucor and all reagent information
was provided on package inserts. Anti-D-series 4 was
a blend of monoclonal immunoglobulin M (IgM) and
IgG anti-D from human/murine heterohybridoma
(MS201 and MS26). Anti-D-series 5 was a blend of
monoclonal IgM and IgG anti-D from human/murine heterohybridoma (Th28 and MS26). Anti-A and
anti-B were murine monoclonal reagents. A1 and
B cells were a 2% to 4% suspension of pooled C-DE- RBCs. Agglutination of the patient RBCs with
anti-A, anti-B, anti-D-series 4, or anti-D-series 5 indicated the presence of the corresponding antigen, and
agglutination of patient serum with A1 or B cells established a positive test. Patients who had an anti-Dseries 4 and anti-D-series 5 numerical value of greater
than or equal to 65 were interpreted as Rh positive.
Patients who did not meet this qualification moved
onto manual testing.
Patients who qualified for manual analysis had their
RBCs tested with the anti-D monoclonal reagent validated for tube testing. This process is detailed in ❚Figure 1❚.
Samples
This study was approved by the Institutional Review
Board at Henry Ford Hospital. At Henry Ford Hospital,
there were 39,048 type and antibody screen samples in
2016, 41,534 in 2017, and 42,537 in 2018. Since our study
sample ended on June 20, 2018, there were approximately
21,269 samples in 2018. In total, during this study period,
there were approximately 101,851 samples. In total, there
were approximately 101,851 samples. These numbers include repeat patients. A total of 106 patients showed inconclusive automated anti-D results from January 1, 2016,
to June 20, 2018. Only women of childbearing potential
(classified as <50 years at our institution) were included in
the final analyses. Four samples were excluded from molecular testing due to either being female and older than
50 years or being male. Subsequently, final analyses had
102 patients for consideration. Patient age, race, and residence zip codes were abstracted from the electronic medical record system, Epic Hyperspace (Epic Systems). To
determine relative proximity to the Henry Ford Hospital
in Detroit, each patient’s zip code was abstracted and entered into MapQuest along with Henry Ford Hospital’s zip
code. The resulting distance was recorded in miles. All analyses were conducted with deidentified data. A spreadsheet
application was used for capturing, presenting, and calculating the data.

© American Society for Clinical Pathology
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reagents. Patients with these results at our institution are
classified as having a Rh typing problem. However, only
molecular testing can differentiate the RHD gene as being
fully expressed or having a variant expression.3
Most studies exploring weak D phenotypes and
genotypes are of European cohorts; therefore, many published studies do not broadly address Black populations.4,5
However, it has been shown that RHD allele frequencies
vary among various racial and ethnic groups.6-10 It is crucial to point out that Black populations have a higher
prevalence of particular RHD alleles; therefore, these patient populations do not follow the standard literature—
and clinical recommendations that have been crafted from
the literature—so it is imperative that population-specific
policies regarding genotypes, molecular results, blood
products given, and RhIG are followed.11
RhD discrepancies pose the most threat to women
of childbearing potential (designated as women
<50 years at our institution). Depending on the RHD
variant identified through molecular testing, these
women have the potential to develop anti-D if exposed
to the RhD antigen during pregnancy.12 In these patients, it is vital to assign the proper D-antigen status
to determine if they can receive RhD-positive or RhDnegative RBCs safely or, if pregnant, to determine if
RhIG prophylaxis is necessary.3 Detroit has a unique
and diverse patient population, and Henry Ford
Hospital has developed a pilot program to identify
the genetic RHD status of qualifying RhD-discrepant
patients. Determining the RHD status of this cohort
of women will not only aid in accurately conserving
RhD-negative RBCs but also allow for the proper administration of RhIG prophylaxis in this specific patient population, when applicable. In addition, we
aimed to report the prevalence of both partial and
weak Ds in the patient population served at our medical center located in Detroit. For practical purposes at
our institution, we nominate women at risk of making
an allo-anti-D as RhD negative and women who do
not have the possibility of making an allo-anti-D as
RhD positive.
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Molecular Analysis
Molecular analysis was conducted at 2 reference laboratories: Versiti Blood Center of Wisconsin and the
American Red Cross in Detroit. Molecular testing was
performed using end-point fluorescence detection based
on sequence-specific amplification polymerase chain reaction. This assay detected the most common weak D alleles: type 1, 1.1, 2, 3, 4, 4.0, 4.1, 4.2 (DAR), 5.11, 14, 15,
and 17 as well as the 3 most common DEL alleles: DEL
(M2951), DEL (K409K), and DEL (IVS3 + IG > A). In
addition, this assay also detected the most frequent partial D alleles: DIIIa, DIIIb, DIIIc, DIVa, DIVb, DIVa
type 3, DIV type 4, DV, DV type 2, DV type 5, DBS1, DBS-2, DCS, DVI type 1, DVI type 2, DVI type 3,
DVI type 4, DVII, DAR, DAU0, DAU1, DAU2/DAU6,
DAU3/DAU11, DAU4, DAU5, DAU7, DAU 8-10 and
12-15, DBT type 1, DBT type 2, DFR, DHMi, DHAR,
and DNB as well as nonfunctional RHD alleles. Per
molecular laboratory recommendations during 2016 to
2018, patients with weak D allele 4.2(DAR) and weak D
allele type 4.0/4.1 were nominated as RhD negative.

Results
Molecular Analysis
Molecular analyses yielded conclusive results in cases
with serologic discrepancies. In total, 13 of 102 (12.7%)
patients were characterized as RhD positive and 89 of
102 (87.3%) patients were characterized as RhD variants
(nominated as RhD negative for practical purposes).

© American Society for Clinical Pathology

Among those that were classified as weak D, the following alleles, with their respective frequencies, were identified: 4 (3.9%) type 3, 0 (0.0%) type 2, 6 (5.9%) type 1, 1
(0.9%) Rh gene detected, 2 (2.0%) no partial D detected,
11 (10.8%) Rh*weak partial 4.0, 43 (42.2%) type 4.0/4.1,
and 5 (4.9%) type 4.2 (DAR). Among those that were
classified as partial D, the following alleles, with their respective frequencies, were identified: 3 (2.9%) RHD*weak
partial D 4.0/RHD*Ψ, 3 (2.9%) DVII, 3 (2.9%) partial
DAU-4 or 5, 6 (5.9%) unknown weak/partial D type, and
15 (14.7%) other partial D allele. ❚Table 1❚ illustrates the
Rh genotype, partial or weak D classification per the molecular laboratory test results, number of patients (and
percentage of total n = 102), and the institutional nomination of RhD negative or RhD positive for practical
considerations.

Racial Classification Analysis
Among this cohort, patients self-identified as
73 (71.5%) Black, 23 (22.5%) White, 1 (0.9%) Asian
American, 4 (3.9%) other, and 1 (0.9%) unknown. ❚Figure
2❚ presents the racial characteristics and respective frequencies identified in this patient cohort.
In the RhD-variant classification (RhD-negative
nomination), there were 69 (67.6%) Blacks, 15 (14.7%)
Whites, 1 (0.9%) Asian American, 3 (2.9%) other, and 1
(0.9%) unknown. In the RhD-positive classification, there
were 4 (3.9%) Blacks, 8 (7.8%) Whites, 0 (0.0%) Asian
Americans, 1 (0.9%) other, and 0 (0.0%) unknown.
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❚Figure 1❚ RhD and molecular determination process used at Henry Ford Health System Blood Bank.
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❚Table 1❚
Rh Genotype Data
Partial D or Weak D Classification

No. of Patients (%)

Institutional RhD Nomination

Type 1
Type 2
Type 3
Rh gene detected
No partial D detected
Rh*weak partial 4.0
RHD*weak partial D 4.0/RHD*Ψ
Type 4.0/4.1*
Type 4.2 (DAR)*
DVII
Partial DAU 4 or 5
Unknown weak/partial D type
Other
Total

Weak D
Weak D
Weak D
Weak D
Weak D
Weak D
Partial D
Weak D
Weak D
Partial D
Partial D
Partial D
Partial D

6 (5.9)
0 (0.0)
4 (3.9)
1 (0.9)
2 (2.0)
11 (10.8)
3 (2.9)
43 (42.2)
5 (4.9)
3 (2.9)
3 (2.9)
6 (5.9)
15 (14.7)
102 (100)

RhD positive
RhD positive
RhD positive
RhD positive
RhD positive
RhD negative
RhD negative
RhD negative
RhD negative
RhD negative
RhD negative
RhD negative
RhD negative

❚Table 2❚
Self-Identified Black Racial Classification, Geographic
Proximity to Henry Ford Hospital, Number of Patients, and
Percentage of Total Blacks Tested (n = 73)
RhD Institutional Nomination

<5 Miles

RhD negative 15 (20.5)
RhD positive 0 (0.0)

>5 and
<10 Miles

>10 and
<15 Miles

>15
Miles

26 (35.6)
3 (4.1)

8 (11.0)
0 (0.0)

20 (27.4)
1 (1.4)

Data are No. (%).

❚Figure 2❚ Self-identified racial classification and numbers of
patients in Detroit, Michigan.

Our results demonstrate that a little over half of our
cohort lived within 15 miles of Henry Ford Hospital. This
is in contrast to the White category where the majority
were noted to live greater than 15 miles away from Henry
Ford Hospital. ❚Table 2❚ presents the patients that identified as Black, their relative proximity to Henry Ford
Hospital, and their corresponding RhD nomination.
Table 2 demonstrates that the majority of Blacks that
were nominated as RhD negative lived within 15 miles of
the hospital.

Discussion
It is important to distinguish between the 3 categories
of the D antigen because the risk of alloimmunization is
more prevalent in certain groups. The D antigen category
has been traditionally thought of as a mosaic with various
puzzle pieces—or epitopes—present.1 However, some of
those pieces can be missing—this is where we have what is
4
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considered a partial D.1 On a molecular level, partial Ds
arise from RHD/CE hybrid alleles, missense mutations in
the extracellular loops, or amino acid substitutions.13 As
a result, when a partial D individual gets transfused with
RhD-positive RBC, alloimmunization can occur because
the individual can produce a D-antibody to the epitope(s)
of the D antigen mosaic they lack.1 Common partial D
categories include DII to DVII, DBT, DFR, DHAR, and
DAU-5, among others.1 The historic understanding has
been that partial Ds can produce an antibody response,
while those with a weak D cannot; however, this interpretation does not hold true anymore.1
Weak D antigens are more complex to define as their
definition regarding epitopes is not as straightforward.1
From a molecular standpoint, weak Ds can arise from
missense mutations.13 The overarching theme throughout
transfusion history, however, has been that most weak D
antigens have a normal D antigen.14-16 This has prompted
clinicians to disregard the possibility of alloimmunization
in weak D patients.16,17 However, weak Ds need to be interpreted with caution as it has now been proven that
there are some weak D antigens that have been associated
with an allo-anti-D.4 For example, DAR types and types
4.2, 11, 15, 21, and 57 are under the weak D classification,
but they have been associated in patients who have made

© American Society for Clinical Pathology
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cohorts cannot be applied to populations of mixed origin
or populations that are predominantly Black.
Various studies have uncovered racial and ethnic patterns in various blood group antigens and specifically
the D antigen.28,29 Dezan et al28 specifically found that
the prevalence of partial D among individuals of mixed
origin—a mixture of European and African decent—was
high. Knowing that Detroit’s racial and ethnic composition does not fit the European cohorts that are prevalent in most research studies, we decided to quantify the
prevalence of variant RhDs in this patient population so
we could learn the needs of our community and provide
population-specific care to serve them better. Our cohort
produced 73 (71.5%) patients that identified as Black and
23 (22.5%) patients that identified as White. Furthermore,
we were able to find that 69 Black patients (93.2% of patients in the Black category) were RhD variants (RhDnegative nomination) after molecular results. Overall,
taking our entire cohort into account, 89 (87.3%) were
candidates for RhIG prophylaxis.
Our study was consistent with a research study
conducted by Bub et al30 in which the researchers had
a multiethnic cohort that was a mix of European,
African, and Native American in their ethnic background. In their cohort of 104 patients with D antigen
serologic discrepancies, they found that 22% of pregnant women were not at risk for producing anti-D while
78% of pregnant women were at risk (definitive and potential) for producing anti-D and were candidates for
RhIG.30 Furthermore, we looked at the number of patients that had weak D alleles that needed to be treated
as RhD negative: types 4.0/4.1 and 4.2 (DAR). We
further analyzed these 2 alleles among Blacks ❚Figure
3❚. We found that a high proportion of Blacks (34 out
of 43 total) tested positive for type 4.0/4.1. This further supports our theory that women of childbearing
potential in Black communities, like Detroit, are at an

❚Figure 3❚ Numbers of weak D allele types that need to be
treated as RhD-negative among Black patients.

Am J Clin Pathol 2021;XX:1-7
DOI: 10.1093/ajcp/aqab061

5

Downloaded from https://academic.oup.com/ajcp/advance-article/doi/10.1093/ajcp/aqab061/6288020 by Henry Ford Hospital user on 18 June 2021

an anti-D.18 Therefore, women of childbearing potential
with these types need to be evaluated for RhIG prophylaxis. Similarly, weak D type 4.0 has also been known to
cause anti-D alloimmunization in some patients.19,20
Additionally, the D antigen has been proven to be
one of the most immunogenic blood group antigens.21 Its
implications in fetal-maternal medicine were first proven
by Chown22 by showcasing that fetal RBCs could cross
the placenta and enter maternal circulation, which could
consequently cause a fetal-maternal hemorrhage. In the
case of an RhD-incompatible pregnancy, with the mother
being RhD negative and the baby RhD positive, the fetal
maternal hemorrhage could cause alloimmunization in
the mother, which could potentially lead to HDFN in the
current or any subsequent pregnancy.
In developed countries, to reduce the risk of
HDFN, the administration of antepartum and postpartum RhIG to RhD-negative mothers has become
standard practice. Overall, RhIG has proven to be successful in reducing the risk of HDFN.23 A meta-analysis
performed by Jones et al23 concluded that in 2 United
Kingdom nonrandomized, community studies, the risk
of sensitization had an associated odds ratio of 0.37
and an absolute reduced risk to 0.6% for RhD-negative
mothers carrying RhD-positive children. More recently,
it has been proven that the administration of RhIG in
first pregnancies reduces the risk of sensitization to approximately 0.2%.24
Challenges, however, arise when RhD variants are
introduced. Currently, serologic techniques do not allow
us to distinguish between weak D and partial D; molecular assays are the only method that allows this distinction between weak D or partial D.3 Furthermore,
even that distinction is not enough as it has been shown
that there are certain weak Ds that can produce an alloanti-D; therefore, specific allele types have to be known.4
Earlier studies have shown that approximately 90% of
Europeans with a serologic weak D have weak D types 1
to 4.25 Therefore, at the time, the authors concluded that
these individuals could be safely transfused with RhDpositive RBCs and were not candidates for RhIG prophylaxis.25 However, there has been a slight change to this
in recent years. There have been many studies that recommend treating weak D type 4.0 as RhD negative and
administering RhIG prophylaxis.4,18,26 Nonetheless, this is
not consistent with our results because our population is
not a predominantly European population. A study conducted by Schulz et al27 found that the racial composition
of Detroit was 57% Black, 22% Latino, and 19% White.
In our Detroit cohort, approximately 12.7% were classified as weak D and RhD positive. Therefore, this paradigm where the molecular results are based on European
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increased risk for having serologic D antigen discrepancies that are consistent with potential alloimmunization
and HDFN.
To understand our community better, we also looked
at geographic proximity of our patients in relation to
Henry Ford Hospital. Our study concluded that the
majority of these patients (50.9%) lived within 15 miles
of Henry Ford Hospital. We also looked at the Black
population and their relative proximity to Henry Ford
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In conclusion, this cross-sectional study gives clinical relevance and insight into the diversity of the D antigen among populations that do not identify as White.
We have shown that approximately 12.7% of our Black
majority cohort classified as RhD positive and 87.3%
classified as RhD variants (RhD-negative nomination
at our institution). These results can facilitate the proper
management of obstetric populations in this patient population. Lastly, the proper RhD-negative or RhD-positive
treatment of Rh variants goes beyond the preservation of
RhD-negative RBCs; it can help mitigate the potential
adverse fetal maternal outcomes.
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